About this trial
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction improves when looking at HPV integration along with TRAF3 and CYLD mutations.
Eligibility criteria
Qualifiers
≥ 18 years of age
T0-T2 N2a-N3 M0 or T3-T4 N0-N3 M0 (AJCC 7th edition)
Biopsy proven squamous cell carcinoma of the oropharynx or unknown primary
No prior therapy
Disqualifiers
Prior history of radiation therapy to the head and neck
Prior history of head and neck cancer.
Inadequate pre-treatment tissue sample for tumor genomic analyses
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
UNC Lineberger Comprehensive Cancer Center
Lead sponsor
Mayo Clinic
Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)
Collaborator